876147-53-4

Usage

Molecular weight

394.89 g/mol The relative molecular mass of the compound, based on the atomic weights of the elements present.

Structure

Complex The compound has a complex structure, featuring various functional groups and a multi-ring system.

Functional groups

Ester, Thiazolyl, Chlorophenyl, and Piperidine The compound contains an ester group (-COO-), a thiazolyl group (a 5-membered ring with a sulfur atom), a chlorophenyl group (a phenyl ring with a chlorine atom), and a piperidine ring (a 6-membered nitrogen-containing ring).

Esterification

1,1-dimethylethyl ester The carboxylic acid group in the compound is esterified with a 1,1-dimethylethyl group (-OC(CH3)3).

Pharmaceutical research

Potential therapeutic properties This chemical is often used in pharmaceutical research and drug development due to its potential therapeutic properties.

Safety precautions

Handle with care Due to the complex structure and potential reactivity of the compound, it is important to handle it with care and ensure proper safety precautions are in place.

Upstream product

• 162167-97-7 tert-butyl 3-(aminomethyl)piperidine-1-carboxylate 
• 54001-17-1 2-(4-chlorophenyl)-4-methyl-1,3-thiazole-5-carboxylic acid 

Downstream Products

• 910805-01-5 (Z)-N-[1-[2-(2-methylthio-2-methylsulfinylethenyl)phenyl]piperidin-3-ylmethyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide 
• 910805-02-6 (E)-N-[1-[2-(2-methylthio-2-methylsulfinylethenyl)phenyl]piperidin-3-ylmethyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide 
• 910805-00-4 N-[1-(2-formylphenyl)piperidin-3-ylmethyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide 
• 876147-54-5 N-(piperidin-3-ylmethyl)-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide 

Relevant academic research and scientific papers

NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE

The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

NOVEL CYCLIC AMINOPHENYLALKANOIC ACID DERIVATIVE

The present invention provides cyclic aminophenylalkanoic acid derivatives that act as agonists for human peroxisome proliferator-activated receptors (PPARs), in particular human PPARα isoform, and are effective in the treatment of abnormal lipid metabolism, diabetes and other disorders. The present invention also provides addition salts of such cyclic aminophenylalkanoic acid derivatives and pharmaceutical compositions containing these compounds. Specifically, the present invention provides cyclic aminophenylalkanoic acid derivatives represented by the following general formula (1) : or pharmaceutically acceptable salts thereof.